TABLE IV. The characteristics of the patients at the 180-day visit (from the univariate analysis).
| Cured patients (%) n = 46 | Not cured patients (%) n = 7 | |
| Age (median, IQR), years | 42.5 (29.7-59.7) | 42 (33-53) |
| Sex (male: female) | 29:17 | 3:4 |
| Lesion location, No. (%) | ||
| Lower limbs | 22 (47.8) | 3 (42.8) |
| Arms/hand | 22 (47.8) | 2 (28.6) |
| Trunk | 8 (17.4) | 0 |
| Head/neck | 3(6.5) | 2 (28.6) |
| Patients with more than one lesion | 7 (15.2) | 0 |
| Feature of the main lesion - ulcerated, n (%) | 42 (91.3) | 7 (100) |
| Site of the main lesion - lower limbs, n (%) | 20 (43.5) | 3 (42.8) |
| Total lesions area (median, IQR), mm2 | 465 (214.2-709.2) | 390 (156-702) |
| Patient weight | 67 (59.8-81.1) | 68.2 (53.3-82.2) |
| Diameter of the main lesion (mean, SD), mm | 23.5 ± 8.9 | 27.3 ± 9 |
| Montenegro skin test positivity, n/N (%) | 16/17 (94.1) | 3/4 (75) |
| Imprint smear positive, n/N (%) | 30/40 (75) | 3/4 (75) |
| Positive Leishmania culture, n/N (%) | 32/42 (76.1) | 5/6 (83.3) |
| Positive Leishmania PCR, n/N (%) | 6/46 (13) | 1/7 (14.2) |
| Illness duration (median, IQR), weeks | 12 (8-16) | 9 (7-12) |
| Hypertension, n (%) | 10/46 (21.7) | 3/7 (42.8) |
| Diabetes, n (%) | 1 (2.1) | 0 |
| Number of infiltrations (median, IQR) | 6.5 (4-8) | 7 (5-8) |
| Total volume of Glucantime® infiltrated (mean, SD), mL | 55.1 ± 92 | 32 ± 17 |
| Total antimony dose infiltered (median, IQR), mg | 2324 (1215-3709) | 1984 (1782-4131) |
IQR: 25-75% interquartile range; SD: standard deviation.